An Exercise Intervention During Chemotherapy for Women With Recurrent Ovarian Cancer A Feasibility Study

被引:44
|
作者
Mizrahi, David [1 ,2 ]
Broderick, Carolyn [1 ]
Friedlander, Michael [1 ,3 ]
Ryan, Mary [3 ]
Harrison, Michelle [4 ]
Pumpa, Kate [5 ]
Naumann, Fiona [6 ]
机构
[1] Univ New S Wales, Sch Med Sci, Sydney, NSW, Australia
[2] Sydney Childrens Hosp, Kids Canc Ctr, Sydney, NSW, Australia
[3] Royal Hosp Women, Gynaecol Oncol, Sydney, NSW, Australia
[4] Prince Alfred Hosp, Royal Sydney Canc Ctr, Sydney, NSW, Australia
[5] Univ Canberra, Res Inst Sport & Exercise, Canberra, ACT 2601, Australia
[6] Queensland Univ Technol, Sch Exercise & Nutr Sci, Brisbane, Qld 4001, Australia
关键词
Cancer; Oncology; Exercise; Physical activity; Chemotherapy; Quality of life; QUALITY-OF-LIFE; PHYSICAL-ACTIVITY; VALIDATION; FATIGUE; THERAPY; RESISTANCE; SYMPTOMS; SAFETY;
D O I
10.1097/IGC.0000000000000460
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective The aim of this study was to determine the feasibility of a combined supervised and home-based exercise intervention during chemotherapy for women with recurrent ovarian cancer. Secondary aims were to determine the impact of physical activity on physical and psychological outcomes and on chemotherapy completion rates. Methods Women with recurrent ovarian cancer were recruited from 3 oncology outpatient clinics in Sydney and Canberra, Australia. All participants received an individualized exercise program that consisted of 90 minutes or more of low to moderate aerobic, resistance, core stability, and balance exercise per week, for 12 weeks. Feasibility was determined by recruitment rate, retention rate, intervention adherence, and adverse events. Aerobic capacity, muscular strength, fatigue, sleep quality, quality of life, depression, and chemotherapy completion rates were assessed at weeks 0, 12, and 24. Results Thirty participants were recruited (recruitment rate, 63%), with a retention rate of 70%. Participants averaged 196 138 min.wk of low to moderate physical activity throughout the intervention, with adherence to the program at 81%. There were no adverse events resulting from the exercise intervention. Participants who completed the study displayed significant improvements in quality of life (P = 0.017), fatigue (P = 0.004), mental health (P = 0.007), muscular strength (P = 0.001), and balance (P = 0.003) after the intervention. Participants completing the intervention had a higher relative dose intensity than noncompleters (P = 0.03). Conclusions A program consisting of low to moderate exercise of 90 min.wk was achieved by two-thirds of women with recurrent ovarian cancer in this study, with no adverse events reported. Randomized control studies are required to confirm the benefits of exercise reported in this study.
引用
收藏
页码:985 / 992
页数:8
相关论文
共 50 条
  • [31] Feasibility Study of Transarterial Chemotherapy Followed by Chemoembolization for Recurrent Breast Cancer
    Hori, Atsushi
    Kennoki, Norifumi
    Hori, Shinichi
    Oka, Shuto
    Nakamura, Tatsuya
    Dejima, Ikuo
    Kumamoto, Akihiko
    Takao, Shintaro
    Sonomura, Tetsuro
    JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2024, 35 (04) : 516 - 522
  • [32] An exercise and nutrition intervention for ovarian cancer patients during and after first-line chemotherapy (BENITA study): a randomized controlled pilot trial
    Maurer, Tabea
    von Grundherr, Julia
    Patra, Stefan
    Jaeger, Anna
    Becher, Heiko
    Schmalfeldt, Barbara
    Zyriax, Birgit-Christiane
    Chang-Claude, Jenny
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 (04) : 541 - 545
  • [33] Study protocol of an exercise and nutrition intervention for ovarian cancer patients during and after first-line chemotherapy (BENITA) - a randomized controlled trial
    Maurer, Tabea
    Belau, M. H.
    Zyriax, B-c.
    Welsch, G.
    Jagemann, B.
    Chang-Claude, J.
    Daubmann, A.
    Buchholz, A.
    Glismann, K.
    Moeller, A.
    Sehouli, J.
    Woopen, H.
    Wimberger, P.
    Harter, P.
    Kaiser, S.
    Maass, N.
    Kiechle, M.
    Engler, T.
    Schmalfeldt, B.
    Schulz, H.
    BMC CANCER, 2024, 24 (01)
  • [34] A FEASIBILITY STUDY OF COMBINATION TAXOL & CARBOPLATIN INTRAPERITONEAL CHEMOTHERAPY IN OVARIAN CANCER
    Park, Y.
    Kim, H. B.
    Rhim, C. C.
    Seong, J. Y.
    Kim, S. J.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (09) : 286 - 287
  • [35] HYPERTHERMIC INTRAPERITHONEAL CHEMOTHERAPY (HIPEC) FOR OVARIAN CANCER TREATMENT: THE FEASIBILITY STUDY
    Lomnytska, M.
    Silins, I.
    Graf, W.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A488 - A489
  • [36] Feasibility and Tolerability of Intraperitoneal Chemotherapy in Ovarian Cancer
    Tasca, G.
    Frezzini, S.
    Baldoni, A.
    Aliberti, C.
    Nicoletto, M. O.
    Conte, P.
    ANNALS OF ONCOLOGY, 2016, 27
  • [37] Intraperitoneal chemotherapy for ovarian cancer: a question of feasibility?
    Willemse, PHB
    de Vries, EGE
    DRUG RESISTANCE UPDATES, 2003, 6 (04) : 165 - 167
  • [38] Priority assessment for women with recurrent ovarian cancer: a pilot study
    Carr, Caitlin
    Bressler, Toby
    Hammer, Marilyn
    Frey, Melissa
    Ellis, Annie
    Shao, Theresa
    Mazzola, Emanuele
    Pozzar, Rachel
    Kolev, Valentin
    Cohen, Samantha
    Hayes, Monica Prasad
    Ruiz, Meghan
    Blank, Stephanie
    GYNECOLOGIC ONCOLOGY, 2021, 162 : S31 - S31
  • [39] Exercise Among Women With Ovarian Cancer: A Feasibility and Pre-/Post-Test Exploratory Pilot Study
    Zhang, Xiaochen
    McClean, Daniel
    Ko, Emily
    Morgan, Mark A.
    Schmitz, Kathryn H.
    ONCOLOGY NURSING FORUM, 2017, 44 (03) : 366 - 374
  • [40] Physical exercise during adjuvant chemotherapy for colorectal cancer-a non-randomized feasibility study
    Hatlevoll, I.
    Oldervoll, L. M.
    Wibe, A.
    Stene, G. B.
    Stafne, S. N.
    Hofsli, E.
    SUPPORTIVE CARE IN CANCER, 2021, 29 (06) : 2993 - 3008